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NK Cells with KIR2DS2 Immunogenotype Have a Functional
Activation Advantage To Efficiently Kill Glioblastoma and
Prolong Animal Survival
Andrea Gras Navarro,*,1 Justyna Kmiecik,*,1 Lina Leiss,*,† Mateusz Zelkowski,*
Agnete Engelsen,* Øystein Bruserud,‡ Jacques Zimmer,x Per Øyvind Enger,*,† and
Martha Chekenya*
Glioblastomas (GBMs) are lethal brain cancers that are resistant to current therapies. We investigated the cytotoxicity of human
allogeneic NK cells against patient-derived GBM in vitro and in vivo, as well as mechanisms mediating their efficacy. We demon-
strate that KIR2DS2 immunogenotype NK cells were more potent killers, notwithstanding the absence of inhibitory killer Ig–like
receptor (KIR)-HLA ligand mismatch. FACS-sorted and enriched KIR2DS2+ NK cell subpopulations retained significantly high
levels of CD69 and CD16 when in contact with GBM cells at a 1:1 ratio and highly expressed CD107a and secreted more soluble
CD137 and granzyme A. In contrast, KIR2DS22 immunogenotype donor NK cells were less cytotoxic against GBM and K562, and,
similar to FACS-sorted or gated KIR2DS22 NK cells, significantly diminished CD16, CD107a, granzyme A, and CD69 when in contact
with GBM cells. Furthermore, NK cell–mediatedGBMkilling in vitro depended upon the expression of ligands for the activating receptor
NKG2D andwas partially abrogated by Ab blockade. Treatment of GBMxenografts in NOD/SCIDmice with NK cells from aKIR2DS2+
donor lacking inhibitory KIR-HLA ligand mismatch significantly prolonged the median survival to 163 d compared with vehicle controls
(log-rank test, p = 0.0001), in contrast to 117.5 d (log-rank test, p = 0.0005) for NK cells with several inhibitory KIR-HLA ligand
mismatches but lacking KIR2DS2 genotype. Significantly more CD56+CD16+ NK cells from a KIR2DS2+ donor survived in non-
tumor-bearing brains 3 wk after infusion compared with KIR2DS22 NK cells, independent of their proliferative capacity. In con-
clusion, KIR2DS2 identifies potent alloreactive NK cells against GBM that are mediated by commensurate, but dominant, activating
signals. The Journal of Immunology, 2014, 193: 6192–6206.
G
lioblastoma (GBM) is the most frequent and malignant
brain tumor in adults (1) and is treated by surgical
debulking, followed by concurrent temozolomide che-
motherapy and fractionated radiotherapy. Despite this aggressive
multimodal treatment, the median survival of patients remains
only 14.6 mo (2) and emphasizes the need for developing novel
and more effective adjuvant treatments.
Several studies investigated the efficacy of adoptively transferred
autologous lymphokine-activated killer cells (3) but a meager few
investigated purified NK cells (4) against GBM. Moreover, the
T cell component of lymphokine-activated killer cells can inhibit
NK cells’ activity due to the development of regulatory T cells (5).
We recently demonstrated elevated expression of MHC class I
molecules on patient GBM cells that may render tolerant autolo-
gous NK cells (6). Therefore, we hypothesized that adoptive
transfer of purified allogeneic NK cells that are killer Ig–like re-
ceptor (KIR)-HLA class I ligand mismatched to the patient’s tu-
mor might be more efficient. NK cells are innate lymphoid cells
that are specialized to recognize and kill tumor- and virus-infected
cells through germline-encoded receptors that transmit activating
or inhibitory signals (7). Natural cytotoxicity receptor (NCRs)
are activating receptors that recognize a variety of viral and bac-
terial molecules expressed on infected cells, as well as ligands
expressed on cancer cells (8). However, many of these ligands
have not been identified. Ligation of NKG2D, a member of the
NK group 2 (NKG2) receptors, to stress-induced molecules, which
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are expressed most frequently on cancer cells, results in NK cell
activation (9, 10). In contrast, NKG2A receptor mediates inhibi-
tory signals upon recognition of HLA-E molecules that are often
upregulated on cancer cells to escape the immune system (11).
KIRs recognize classical MHC class I (HLA-ABC in humans).
KIRs with short cytoplasmic domains are activating receptors,
whereas ligation of the KIR with long cytoplasmic domains to
their cognate HLA class I ligands transmits a cascade of inhibitory
signals that mediates NK cell tolerance to self cells (12). A
number of malignancies have been associated with particular KIR
genotypes [e.g., reduced frequency of KIR2DS2 was reported in
pre-B acute lymphoblastic leukemia (13), as well as KIR2DL2
and KIR2DS2 in autologous NK cells from chronic myeloid
leukemia patients (14)]. Limited literature exists on the predictive
potential and functionality of KIR immunogenotypes in solid
tumors (15, 16), in particular GBM. NK cells display cytotoxicity
against altered self cells that downregulate HLA class I molecules
as a result of the “missing self” mechanism (17). However, KIR-
HLA class I ligand mismatch can occur in an allogeneic setting
when the donor’s NK cells express KIRs that do not recognize the
recipient’s HLA class I molecules, resulting in diminished in-
hibitory signals for NK cells (18). In addition, when activating
KIR, NKG2D and NCRs are ligated to their cognate ligands, the
balance may be tipped towards activating signals, and this ulti-
mately determines cytotoxic potency (19) and production of
proinflammatory cytokines and chemokines. Thus, the therapeutic
potential of NK cells against cancer was explored in vitro (20–22)
and in vivo (23, 24). Allogeneic NK cells were demonstrated to
mediate the graft-versus-leukemia effect through KIR-HLA class I
ligand mismatch in patients receiving hematopoietic stem cell
transplantation (HSCT) (18). In the current study, we aimed to
elucidate the potential of allogeneic NK cells against GBM. In-
teraction of NKG2D receptor with its ligands expressed on tumor
cells, as well as the presence of KIR2DS2 receptor, had greater
impact on GBM lysis than did the inhibitory KIR-HLA class I
mismatch. KIR2DS2+ NK cell subsets exhibited a functional ac-
tivation advantage, cytokine production, propensity for degranu-
lation, and greater persistence in vivo compared with KIR2DS22
NK cells. To our knowledge, this is the first report demonstrating
efficacy of allogeneic NK cells against patient-derived solid tumor
in vitro and in vivo mediated by alloreactive subpopulations with
dominant functional activation signals.
Materials and Methods
NK cell isolation and culture
This study was approved by the Regional Ethical Committee of Western
Norway, Bergen (2013/96) and informed consent to participate was
obtained from all donors. PBMCs were obtained from the blood of 10
healthy donors using Leucosep 50-ml tubes with a high-density polyeth-
ylene membrane (Greiner Bio-One, Frickenhausen, Germany) and Lym-
phocyte Separation Medium (Lonza, Lysaker, Norway). NK cells were
purified using a human NK Cell Isolation Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany), according to the manufacturer’s protocol. The NK
cells were cultured in CellGro GMP Serum-free Stem Cell Growth Me-
dium (CellGenix, Freiburg, Germany) supplemented with 10% FCS (PAA
Laboratories, Pasching, Austria), 500 U/ml IL-2 (R&D Systems, Abingdon,
U.K.), and the NK Cell Expansion/Activation Kit containing anti-CD2 and
anti-CD335 (NKp46) Abs (Miltenyi Biotec), according to the manu-
facturer’s instructions. After 2 wk of culture, NK cells for in vivo
experiments were washed, and beads were removed using a magnetic
separator (Miltenyi Biotec).
K562 and patient GBM cell culture
GBM cell lines were established from patient biopsies collected during
surgical procedures at Haukeland University Hospital. The Regional Ethical
Committee of Western Norway, Bergen and the Norwegian Data Protection
Agency approved the collection of tumor tissue. Patients gave their in-
formed consent to specimen collection for research purposes, and their
samples were analyzed anonymously. Tumor tissue was mechanically
dissociated as previously described (6). The human chronic myelogenous
leukemia cell line K562 (American Type Culture Collection, Manassas,
VA) was cultured in suspension with RPMI 1640 medium supplemented
with 10% FCS, 5% penicillin-streptomycin, and 1 mM HEPES at 37˚C and
5% CO2. GBM primary cultures obtained from patients P3 (GBM), 2012-
018 (GBM with gliosarcoma differentiation), and 2011-20-I (GBM) were
propagated in Neural Basal medium (Invitrogen, Hämeenlinna, Finland)
supplemented with 1% GlutaMAX (Invitrogen), 2% B-27 (Invitrogen), 5%
penicillin-streptomycin (Lonza), 10 mg/ml epidermal growth factor, and
fibroblast growth factor (PeproTech) at 37˚C and 5% CO2. Cells in ex-
ponential growth phase were used for all assays.
GBM spheroid culture
For in vivo experiments, P3 GBM cells were propagated in vitro as
spheroids in DMEM (Sigma-Aldrich, Oslo, Norway) supplemented with
10% FCS (PAA Laboratories), 100 U/ml penicillin-streptomycin (Lonza),
and 5 mg/ml plasmocin (InvivoGen, Toulouse, France) in (30% v/v) agar-
coated flasks. Standardized spheroids containing 104 cells/spheroid were
cultured in 4% v/v methylcellulose-DMEM in round-bottom 96-well plates
over 3 wk.
DNA isolation, KIR typing, HLA typing, and KIR-HLA
mismatch
DNA was isolated from GBM cells and from the NK cell donors’ blood
using DNeasy Blood & Tissue Kit (QIAGEN, Germantown, MD),
according to the manufacturer’s protocol. The GBM cells’ HLA class I
(loci A, B, and C) was genotyped by ProImmune (Oxford, U.K.) using the
PCR-based sequence-specific oligonucleotide probe hybridization tech-
nique. High-resolution HLA typing (with PCR sequence-specific primers
or PCR sequencing) was performed for the HLA-C locus on 2012-018
cells. The expression of HLA-G and HLA-E was evaluated by flow
cytometry. In addition, the surface expression of selected HLA class I
epitopes was evaluated by flow cytometry using anti–HLA-Bw4, A9, A32,
and anti–HLA-A3 Abs (Abcam, Cambridge, U.K.). KIR typing was per-
formed using the KIR Typing kit (Miltenyi Biotec), according to the
manufacturer’s protocol. KIR-HLA class I mismatch was defined as the
absence of inhibitory signal resulting from absence of the receptor gene in
the donor’s DNA, whereas the ligands’ genes were present in the GBM
cells’ DNA.
In vitro cytotoxicity assays
In vitro cytotoxicity assays were performed with NK cells cultured for
2 wk against GBM cells and the K562 chronic myelogenous leukemia cell
line as a positive control. Target cells were washed and labeled with CFSE
(Sigma-Aldrich). Following the washing steps, NK cells were cocultured
with target cells at E:T ratios of 2:1, 5:1, 10:1, and 20:1 for 4 h at 37˚C and
5% CO2 in RPMI 1640 medium (Invitrogen) supplemented with 10% FCS
(PAA Laboratories), 50 U/ml penicillin-streptomycin (Lonza), and 1 mM
HEPES (Invitrogen). Culture of target cells alone was used as a negative
control. In six cytotoxicity assays we blocked the NK cell receptors using
the following Abs: anti-NKG2D and anti-KIR2DS4 at final concentration
of 5 mg/106 effector cells and anti-KIR2DS2 at a final concentration of
3 mg/106 effector cells (Supplemental Table I). Isotype-control mouse
IgG1 (R&D Systems), mouse IgG2a (R&D Systems), and rabbit IgG
(Abcam) were used at the same concentration as the Ab to which they
corresponded. Each experimental condition was performed in three repli-
cates. Then cells were washed with PBS containing 0.5% BSA (Miltenyi
Biotec) and labeled with a Live/Dead Fixable Near-IR Dead Cell Stain Kit
(Invitrogen), according to the manufacturer’s protocol, or with TO-PRO3
(Invitrogen) for 1 min before data acquisition on a BD LSR Fortessa flow
cytometer (BD Biosciences, Trondheim, Norway). The data were analyzed
using BD FACSDiva v6.2 software (BD Biosciences). The target cells
were identified as CFSE+, and effector cells were identified as CFSE2. The
dead target cells were identified as CFSE+TO-PRO3+ or CFSE+Live/Dead+.
Spontaneous death was defined as the proportion of dead target cells
cultured alone (negative control), and this value was subtracted from the
proportion of dead target cells cocultured with effector cells. Each cyto-
toxicity assay was repeated in at least 3 or 4 independent experiments.
KIR2DS2 cell sorting and activation assays
FACS sorting of KIR2DS2+ and KIR2DS22 NK cells was carried out to
study the functional features of KIR2DS2+ NK cell subsets. Purified NK
cells from KIR2DS2+ donors were sorted after expansion for 2 wk. NK
cells were stained with anti-KIR2DS2 Ab, as described below (“Flow
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cytometry phenotyping”), and 106 cells with the highest fluorescence
intensity and 106 negative cells were sorted using a FACSAria II (BD
Biosciences); cells with intermediate fluorescence intensity were discarded
(see gating strategy in Fig. 2Af). Cells stained with isotype control and
stained KIR2DS2 immunogenotype–negative cells were used as controls
for gating. Data were recorded and analyzed using BD FACSDiva v6.2
software (BD Biosciences) and FlowJo v10 software (TreeStar, Ashland,
OR). After sorting, KIR2DS2+ and KIR2DS22 subsets were expanded for
two additional weeks to obtain greater cell numbers. Then, NK cells were
plated in either monoculture 1:0 or in coculture with GBM cells at an E:T
ratio of 1:1 for 4 h at 37˚C and 5% CO2 in serum-free RPMI 1640 medium
without cytokine supplements. Following the 4-h incubation, supernatants
were collected and stored at 280˚C pending cytokine analysis. The cells
were washed, immunostained, and phenotyped for surface and intracellular
markers.
Cytokine analysis
Supernatants from two independent activation assays (above) were col-
lected and analyzed in duplicate for diverse cytokines, granzymes, and
perforin using a Luminex-based immunoassay and a kit that detected 17
analytes. This Milliplex Human Magnetic Cytokine Bead Panel (cat. no.
HCD8MAG15K-17PMX;MerckMillipore, Darmstadt, Germany) was used
according to the manufacturer’s instructions.
In vivo NK cell therapy for GBM-bearing mice
All animal procedures were performed in accordance with the European
Convention for the Protection of Vertebrates Used for Scientific purposes,
and the protocols were approved by The Norwegian Animal Research
Authority (Oslo, Norway). A total of 40 7-wk-old NOD/SCID mice
(Taconic) of both genders were implanted intracranially with P3 tumor
spheroids. Each animal was anesthetized with sevoflurane (Abbott Labo-
ratories) and secured in a stereotactic frame (Kopf Instruments, Tujunga,
CA). A burr hole was made with a microdrill (Kopf Instruments) 0.5 mm
posterior to the bregma and 2 mm to the right of the sagittal suture. Five
spheres/animal were injected 2 mm below the brain surface with a Hamilton
syringe. One week after implantation, mice were subjected to either of the
following treatments administered intracranially using the same coordinates
as the previously implanted tumor spheroids: 1) 10 ml PBS containing 4.4 g/l
glucose (n = 5) or 2) anti-CD2 and anti-NKp46 Abs at a concentration of
0.05 mg/ml in 10 ml PBS (without conjugated beads) used as control for
NK cell expansion (Miltenyi Biotec) (n = 6) and 3) 106 NK cells from
donor 4 or donor 3 diluted in 10 ml PBS containing 4.4 g/l glucose (n = 14
and n = 16, respectively). Two weeks after implantation, mice were
injected intracranially with a second 10-ml dose of PBS containing glucose
(n = 5), 10 ml Abs (without conjugated beads) used for NK cell expansion
(Miltenyi Biotec) (n = 6), or 106 NK cells from donor 4 or donor 3 diluted
in 10 ml PBS containing glucose (n = 7 and n = 8, respectively), as de-
scribed above. Animals were monitored for survival and inspected daily.
Animals were sacrificed by CO2 inhalation and dislocation of the neck
when they developed neurologic symptoms, such as rotational behavior,
reduced activity, or delayed grooming and dome head. Their brains were
fixed in formalin for H&E and immunohistochemistry (IHC) staining.
In vivo off-target NK cell therapy
A total of 45 7-wk-old NOD/SCID mice (Taconic, Denmark) of both
genders was treated intracranially with 10 ml PBS containing 4.4 g/l
glucose (n = 3) or 106 NK cells from donor 4 (KIR2DS22) or donor 3
(KIR2DS2+) diluted in 10 ml PBS containing 4.4 g/l glucose (n = 18 each)
administered into the same sterotaxic brain coordinates as described in the
section above. One week later, some mice were injected intracranially with
a second dose of 10 ml PBS containing 4.4 g/l glucose (n = 3) or 106 NK
cells from donor 4 or donor 3 diluted in 10 ml PBS containing 4.4 g/l
glucose (n = 13 each), as described above. Three animals from each group
were sacrificed at 1, 3, and 5 wk after the second NK cell dose, and their
brains were dissociated into single-cell suspensions using a Neural Tissue
Dissociation Kit containing papain (Miltenyi Biotec), according to the
manufacturer’s protocol, and analyzed by flow cytometry. The remaining
animals were monitored for survival, inspected daily, and sacrificed when
they developed neurologic symptoms, as described above. Their brains
were fixed in formalin for H&E and IHC staining.
Flow cytometry phenotyping
PBMCs, NK cells, GBM cells, and cells obtained from the dissociated mice
brains were counted and washed with PBS containing 0.5% BSA. The
cells were stained with a Live/Dead Fixable Near-IR or a Yellow Dead Cell
Stain Kit (Invitrogen) and fluorochrome-conjugated Abs (Supplemental
Table I) or isotype controls for 20 min at 4˚C protected from light.
Then, cells were washed, fixed, and permeabilized with Cytofix/Cytoperm
(BD Biosciences), followed by intracellular staining with fluorochrome-
conjugated Abs (Supplemental Table I) or isotype controls for 20 min at
4˚C, protected from light. Cells were washed, and data were acquired
on a BD LSR Fortessa (BD Biosciences) flow cytometer. The data were
analyzed using BD FACSDiva v6.2 software (BD Biosciences) and FlowJo
v10 software (TreeStar). The proportion of specifically stained cells indi-
cated on the graphs was calculated as the percentage of marker-positive
cells subtracting the percentage of isotype control–positive cells. Debris
and dead cells were excluded from the analysis based on a forward scatter
(FSC) versus side scatter (SSC) plot and Live/Dead staining. Doublets
were excluded based on an SSC-A versus SSC-H plot. In the in vivo
experiments, human NK cells were defined as CD45+CD32CD56+ cells,
and human tumor cells were defined as nestin+CD452 cells. Murine im-
mune cells were gated as CD45+ cells by mouse-specific staining.
Microglia and macrophages were defined as CD11b+CD45low and CD11b+
CD45high populations, respectively. In the in vitro experiments, human
NK cell subpopulations were gated based on CD56, CD16 expression, and
lack of CD3. Thereafter, the gated populations were analyzed for expression
of CD4, CD8, NKG2D (CD314), NKp46 (CD335), NKG2A, CD69,
CD107a, Ki-67, IFN-g, and KIRs—KIR2DL4, KIR2DL3, KIR2DL1,
KIR3DL1, KIR3DL2/1, KIR2DL2/3, KIR2DS4, and KIR2DS2 (Supplemental
Table I). To assess the KIR2DS2+ subpopulation, KIR2DS2+ and KIR2DS22
cells were gated (see gating strategy in Fig. 2Ab) and analyzed for the expres-
sion of CD16, CD69, NKG2D, KIR2DL1, KIR3DL1, KIR3DL2/1, and
KIR2DL2/3. Importantly, for good separation of KIR3DL2 and KIR3DL1,
as well as KIR2DL2 and KIR2DL3, two-step staining was performed. NK
cells were preincubated for 20 min with anti-KIR2DL1 and anti-KIR3DL1
Abs before incubation with anti-KIR3DL2/1 and anti-KIR2DL2/3 Abs.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections of the animals’ brains were
subjected to IHC staining using standard procedures (25). Following un-
masking of antigenic determinants, the sections were labeled with the fol-
lowing primary Abs: mouse anti-human nestin (Millipore, Oslo, Norway),
mouse anti-human STEM121 (StemCells, Cambridge, U.K.), mouse anti-
human NKp46 (BioLegend, San Diego, CA), mouse anti-human Ki-67
(Dako, Glostrup, Denmark), and rat anti-mouse CD31 (Dianova, Ham-
burg, Germany). After the washing steps, endogenous peroxidase blocking
was applied, and sections were incubated with secondary Abs. Staining
was visualized with the avidin-biotin-peroxidase complex method with
3,39-diaminobenzidine and H2O2 (DCS, Hamburg, Germany), according to
the manufacturer’s protocol (VECTASTAIN; Vector Laboratories, Bur-
lingame, CA). Thereafter, the sections were counterstained with Harris
hematoxylin. The percentages of Ki-67+ cells (Ki-67 labeling index) and
NKp46+ cells were quantified in five randomly selected high-power (4003
magnification) microscopic fields in all animals in the study group. De-
tection of apoptotic cells was performed with the TUNEL assay, according
to the manufacturer’s instructions (Roche Applied Bioscience, Mannheim,
Germany), and apoptotic cells were quantified as previously described
(25). Quantification of CD31+ microvascular density and area fraction of
CD31+ cells was performed as previously described (25).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed with a 7-Tesla Bruker
PharmaScan system (Bruker, Ettlingen, Germany) and linear-volume
radiofrequency coil with an internal diameter of 23 mm. T1-
weighted MRI was obtained using a rapid-acquisition relaxation en-
hancement sequence with relaxation time = 900 ms, excitation time = 9.00
ms, rare factor = 4, a slice thickness of 1.0 mm, and resolution of 0.0078
cm/pixel. T2-weighted MRI was obtained using a rapid-acquisition re-
laxation enhancement sequence with relaxation time = 3500 ms, excitation
time = 35.22 ms, rare factor = 8, a slice thickness of 1.0 mm, and reso-
lution of 0.0078 cm/pixel. MRI scanning was performed 12, 19, and 26 d
after tumor spheroid implantation (pretreatment, posttreatment 1 and
posttreatment 2, respectively), and MRI scanning longitudinally followed
the same three animals/group. Each measurement involved a tripilot scan,
a T2-weighted scan, a precontrast T1-weighted scan, and a postcontrast
T1-weighted scan, with 0.1 ml Dotarem contrast agent (gadoteric acid
279.3 mg/ml; Guerbet, Roissy, France) injected s.c.
Statistical analyses
Survival data were analyzed using the Kaplan–Meier method with the
Mantel–Cox log-rank test. The phenotyping data obtained by flow cyto-
metry and IHC quantification were analyzed using a nonparametric Mann–
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Whitney U one-way ANOVA with Dunn multiple-comparison post hoc
test or two-way ANOVA with Bonferroni multiple-comparison post hoc
test when more than two categorical and dependent variables were ana-
lyzed. All analyses were performed with Prism statistical software, version
5.0 (GraphPad, La Jolla, CA). The p values , 0.05 were considered sta-
tistically significant.
Results
Expression of GBM stem cell–like markers
Previous studies demonstrated that GBM cells propagated in
growth factor–defined stem cell medium retained tumor hetero-
geneity, resembled glioma stem–like cell (GSC) phenotypes, and
were more susceptible to NK cell lysis (26). Therefore, we char-
acterized the GBM short-term cultures for their expression of
immature differentiation markers and ligands for NK cell recep-
tors (Table I, Supplemental Fig. 1). A high percentage (87–100%)
of P3 and 2011-20-I GBM cells expressed nestin (Table I,
Supplemental Fig. 1H and 1I, respectively), as well as vimentin
and glial fibrillary acidic protein (GFAP) intermediate filaments
(Table I, Supplemental Fig. 1K and 1L, respectively). A total of 40%
of 2012-018 gliosarcoma cells expressed A2B5 (Supplemental
Fig. 1S), 80% expressed GFAP (Supplemental Fig. 1M), and 80.
4% expressed vimentin, consistent with their gliosarcoma differ-
entiation (Table I). Prominin-1/CD133, which was reported to
identify GSCs (27), was expressed by 39% of P3 cells, 31.5% of
2011-20-I cells, and 21.1% of 2012-018 GBM cells (Table I,
Supplemental Fig. 1N–P, respectively). A total of 40.7% of 2012-
018 GBM cells expressed CD15 (Table I), which was reported to
be enriched on CD1332 GSCs (28). P3 and 2011-20-I GBM cells
did not express CD31, whereas 35.2% of 2012-018 gliosarcoma
cells expressed it (Table I). Taken together, the GBM short-term
cultures differentially expressed markers associated with the im-
mature GSC phenotype, as opposed to more differentiated cells.
Expression of HLA class I and II molecules on GBM cells
KIR-HLA class I mismatch was reported to improve the outcome of
leukemia patients receiving HSCT (18) and to play a role in the
NK cells’ cytotoxicity against solid tumors in vitro (21, 29). To
investigate the impact of KIR-HLA class I mismatch on NK cell
potency against GBM, we genotyped the HLA class I alleles and
determined their expression at the protein level. At least 99% of
all GBM cells expressed the classical HLA-A, -B, and -C mole-
cules. None expressed the nonclassical HLA-G, whereas 25.2% of
2012-018 GBM cells expressed HLA-E (Table I, Supplemental
Fig. 1G). A total of 19.5% of 2011-20-I GBM and 63.4% of
2012-018 cells expressed HLA class II molecules, P3 did not
express them (Table I). HLA-class I genotyping of GBM cells was
also performed (Supplemental Table II), and the surface expres-
sion of HLA-A and -B molecules was confirmed by flow cytom-
etry. A total of 98.1% of 2012-018 cells expressed HLA-A3
(Table I, Supplemental Fig. 1D), and 97.5, 77.4, and 97.3 of P3,
2011-20-I, and 2012-018 cells expressed HLA-Bw4, respectively
(Table I, Supplemental Fig. 1A–C, respectively). The 2012-018
cells expressed HLA-A, HLA-B, HLA-C, and HLA-Bw4 at the
highest density, as indicated by mean fluorescence intensity (MFI)
data (Table I). The Ab that we used to detect HLA-Bw4 also
recognizes HLA-A9 and HLA-A39 molecules; however, all cell
lines were negative for these alleles at the genomic level
(Supplemental Table II). Moreover, a number of HLA-A alleles,
as well as HLA-B alleles, including HLA-B*44 and HLA-B*27
present in the genome of P3, HLA-B*44 present in the genome of
2011-20-I, and HLA-B*37 present in the genome of 2012-018,
belong to a group of alleles with the HLA-Bw4 epitope
(Supplemental Table II). Thus, all of the GBM cells differentially
expressed ligands for KIRs.
Purified and ex vivo–expanded NK cells efficiently kill GBM
cells in vitro but are less potent against gliosarcoma cells
We purified NK cells from 10 healthy donors and analyzed phe-
notype, morphology of freshly isolated (resting) and cultured
(activated) NK cells, and expansion rates of NK cells in culture. As
expected, freshly isolated NK cells (CD56+CD32) were predom-
inantly CD56dimCD16+ under steady-states and had a rounded
phase-bright morphology (Supplemental Fig. 1T and 1V, respec-
tively). After 2 wk in culture, the NK cells acquired a CD56bright
CD16bright phenotype and a ramified, phase-dark morphology
(Suppl. Fig. 1U and 1W, respectively). Inhibitory KIRs, NKG2D,
and NKp46 were not significantly affected by culture conditions
(Supplemental Fig. 1X). However, NKG2A receptor expression
was attenuated on activated NK cells (p = 0.0073, Supplemental
Fig. 1X). Although there was a donor-dependent variability, the
purified NK cells were successfully expanded 8.73 6 4.22-fold in
culture (mean 6 SEM, range 5.07–10.82; data not shown). Acti-
vated NK cells from all donors were able to kill the GBM cells;
Table I. Expression of GBM stem–like markers and NK cell ligands
Ligand/Marker P3 (% of Cells) 2011-20-I (% of Cells) 2012-018 (% of Cells) P3 (MFI) 2011-20-I (MFI) 2012-018 (MFI)
ULBP-1 68.23 41 33.2 23,923 36,621 19,524
ULBP-2/5/6 95.22 90.18 71.2 183,413 67,147 58,897
ULBP-3 63.03 50 41.4 28,371 19,871 29,928
MICA 91.03 95.16 91.65 371 344 234
MICB 6.91 13.13 41.22 11,482 43,564 13,626
HLA-A,B,C 99.28 99.7 99.17 1,571 724 9,456
HLA-DR,DP,DQ 0 19.5 63.42 0 466 900
HLA-E 0 0 25.2 0 0 415
HLA-G 0 0 0.1 0 0 971
GFAP 98.8 100 79.98 1,131 1,123 466
Vimentin 95.6 87.6 80.4 1,399 532 3,206
Nestin 97.6 99.7 96.81 6,148 2,115 1,176
CD31 0 0 35.23 0 0 677
CD133 39 31.5 21.12 172 102 419
A2B5 42.6 77.3 40.04 250 489 877
CD15 0.25 0 40.72 0 0 679
HLA-A3 — — 98.1 0 0 5,584
HLA-Bw4 97.5 77.4 97.3 2,354 621 4,802
The proportion of specifically stained cells was calculated by subtracting the percentage of isotype-control–positive cells from the percentage of marker-positive cells.
—, HLA-A3 not present on genotype and not expressed on protein level.
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however, the efficiency was donor dependent (Supplemental Fig.
1Y). 2012-018 cells were significantly less susceptible to NK cell–
mediated lysis compared with P3 and 2011-20-I cells at all E:T
ratios (p , 0.001 and p , 0.0001, respectively, at E:T ratio of
5:1; p , 0.0001 at an E:T ratio of 10:1; and p , 0.05 and p ,
0.0001, respectively, at an E:T ratio of 20:1, Kruskal–Wallis test,
Supplemental Fig. 1Y). No significant difference was observed
between P3 and 2011-20-I cells (Supplemental Fig. 1Y). All donor
NK cells efficiently killed control K562 cells (p , 0.001 and p ,
0.0001 compared with GBM cells, Supplemental Fig. 1Y).
Ligation of NKG2D-activating receptor to stress-induced
ligands is important for NK cell lysis of GBM cells
To investigate the impact of NKG2D on the differential suscep-
tibility of GBM cells to NK lysis, we determined the expression of
its ligands—MHC class I–related chain A (MICA), MHC class
I–related chain B (MICB), and UL16-binding proteins (ULBPs)
by GBM cells. A total of 41.2% of 2012-018 gliosarcoma cells
expressed MICB (Fig. 1Ai, Table I), whereas 6.9 and 13.1% of P3
and 2011-20-I cells, respectively, expressed it (Fig. 1Aa, 1Ae,
respectively, Table I). High percentages (91–95%) of all GBM
cells expressed MICA (Fig. 1Ab, 1Af, 1Aj, Table I). Various
proportions of all three GBMs expressed ULBP-1, ULBP-3 (Fig.
1Ac, 1Ag, 1Ak), and ULBP-2/5/6 (Fig. 1Ad, 1Ah, 1Al) (Table I).
P3 was the GBM with the highest proportion of ULBP-1+, ULBP-3+
(Fig. 1Ac), and ULBP-2/5/6+ (Fig. 1Ad) cells (68.2, 63, and
95.2%, respectively, Table I), followed by 2011-20-I (Fig. 1Ag,
1Ah, respectively; 41, 50, and 90.2%, Table I), whereas 2012-018
had the lowest percentages of positive cells of all three GBMs
(Fig. 1Ak, 1Al, respectively; 33.2, 41.4, and 71.2%, Table I).
2012-018 cells also expressed ULBP-1, ULBP-2/5/6, and MICA
at the lowest density compared with P3 and 2011-20-I cells, as
indicated by the MFI data (Table I).
Next, we performed in vitro cytotoxicity assays with activated
NK cells obtained from six healthy donors against P3 and 2012-018
cells and observed that all donor NK cells efficiently killed the
GBM cells from both sources, although the percentage of lysed
2012-018 cells was lower than P3 cells. Blocking NKG2D receptor
significantly attenuated NK cell–mediated killing of P3 cells at
all E:T ratios, whereas isotype-control IgG1 Abs had no effect
(p = 0.0006 at E:T ratio of 5:1; p , 0.0001 at E:T ratio of 10:1;
and p , 0.0001 at E:T ratio 20:1; Friedman test, NKG2D
blocking compared with controls [no Ab and isotype control],
Fig. 1B). Similar results were obtained for 2012-018 cells
(p = 0.0031 at E:T ratio of 5:1; p = 0.0114 at E:T ratio of 10:1;
and p = 0.0048 at E:T ratio of 20:1; Friedman test, NKG2D
blocking compared with control [no Ab and isotype control],
Fig. 1C). Taken together, these data indicate that activating
signals via NKG2D are important for NK lysis of GBM cells.
However, donor dependency of NK cell lysis of GBM and
the GBM cells’ partial rescue after NKG2D blockade indicated
that other mechanisms contributed to NK cell efficacy.
Activating KIR2DS2 receptor is important for NK cell potency
against GBM cells in vitro, independent of inhibitory KIR
repertoire
To investigate the impact of KIR–HLA interactions between
NK cells and GBM cells, genomic KIR typing of the donors and
HLA class I typing of GBM cells were performed (Table II,
Supplemental Table II). 2012-018 cells expressed all HLA class I
alleles that are known ligands for KIRs (Table I, Supplemental
Fig. 1C, 1D, Supplemental Table II). P3 and 2011-20-I cells
did not express any known ligands for KIR3DL2 (Table I,
Supplemental Table II). Next, we compared the mean percentage
of GBM cells lysed by NK cells isolated from donors expressing
all inhibitory KIRs with lysis by donors missing one inhibitory
KIR and lysis by donors missing two or three inhibitory KIRs. No
significant difference in lysis for any of the GBM cells was ob-
served (data not shown), indicating that KIR-HLA ligand mis-
match was unlikely to be a major mechanism contributing to
GBM killing.
Therefore, we investigated the impact of activating KIR genes
and found that NK cells possessing the KIR2DS2 immunogeno-
type (KIR2DS2+) were significantly more efficient against P3
cells at an E:T ratio of 10:1 (p = 0.0373, Kruskal–Wallis test with
Dunn multiple-comparison test, Fig. 1D) and an E:T ratio of 20:1
(p = 0.0202, Kruskal–Wallis test, Fig. 1D), as well as against
2012-018 cells at an E:T ratio of 5:1 (p = 0.0331, Kruskal–Wallis
test, Fig. 1E), an E:T ratio of 10:1 (p = 0.0056; Kruskal–Wallis
test, Fig. 1E), and an E:T ratio of 20:1 (p = 0.0099, Kruskal–
Wallis test, Fig. 1E), compared with KIR2DS22/KIR2DS42
donors (negative). No significant difference was observed for
2011-20-I tumor cells (data not shown). NK cells from KIR2DS4+
donors were significantly more cytotoxic against 2012-018 cells at
an E:T ratio of 10:1 (p = 0,0056, Kruskal–Wallis test, Fig. 1E) and
an E:T ratio of 20:1 (p = 0.0099, Kruskal–Wallis test, Fig. 1E)
compared with negative donors. These results were independent of
the expression of inhibitory KIRs, because similar levels of ex-
pression were observed in these three groups (data not shown).
The surface expression of KIR2DS2 or KIR2DS4 on cultured NK
cells possessing the KIR2DS2 or KIR2DS4 immunogenotype was
determined by flow cytometry. A total of 36.39 6 19.35% (range:
14.1–86.4%, n = 4) of NK cells from donors with the KIR2DS2+
genotype expressed KIR2DS2 on the cell surface (Fig. 1Fa–d).
KIR2DS4+ subsets accounted for 45.4 6 21.5% in the two donors
possessing the KIR2DS4 immunogenotype (Fig. 1Fe, 1Ff). In
addition, we compared the cytotoxicity of NK cells from donors 4
and 5, who lacked the KIR2DS2 gene but possessed three or more
other activating KIR genes, with NK cells from donors 6 and 7,
who possessed only the KIR2DS2-activating KIR gene (Table II).
The latter NK cells were significantly more cytotoxic against P3
cells at an E:T ratio of 10:1 (p = 0.0127, Mann–Whitney U test,
Fig. 1G) and against 2012-018 cells at an E:T ratio of 10:1
(p = 0.0451, Mann–Whitney U test, Fig. 1H) and an E:T ratio of
20:1 (p = 0.0177, Mann–Whitney U test, Fig. 1H).
KIR2DS2 immunogenotype confers a functional activation
advantage
HLA-A*11:01 was recently identified as a ligand for KIR2DS2
(30). Despite the absence of the HLA-A*11:01 gene on the ge-
notype of the P3, 2012-018, and 2011-20-I cells (Table II,
Supplemental Table II), NK cells from donors with a KIR2DS2+
genotype killed P3 and 2012-018 cells more efficiently than did
NK cells from donors without the KIR2DS2 gene (Fig. 1D, 1E).
Indeed, NK cells with a KIR2DS2+ immunogenotype killed K562
cells lacking HLA ligands significantly better than did KIR2DS22
cells (p = 0.0345, Kruskal–Wallis test, Fig. 1I), pointing against
the KIR–HLA ligand interaction as a mechanism for a cytotoxic
effect. To investigate whether KIR2DS2 conferred an intrinsic
functional advantage over other subpopulations, we investigated
their activation, proliferation, and cytokine production in vitro, as
well as their survival capabilities in vivo in mice without tumors.
We used heterogeneous NK cells isolated from donors possessing
the KIR2DS2 gene (Fig. 2Ab, 2Ac) for in vitro assays. Subse-
quently, we gated the KIR2DS2+ and KIR2DS22 subpopulations
(Fig. 2Ad, 2Ae) and compared them with KIR2DS2 immunoge-
notype–negative NK cells (Fig. 2Aa). Alternatively, KIR2DS2+
and KIR2DS22 NK cell subsets were sorted using FACS (Fig.
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2Af), expanded for 2 wk (Fig. 2Ag) prior to use in assays as gated
KIR2DS2+ of sorted KIR2DS2+ cells, gated KIR2DS22 of sorted
KIR2DS2+ cells, or sorted KIR2DS22 cells (Fig. 2Ah–j, respec-
tively), and compared with KIR2DS22 NK cells (Fig. 2Aa). In
monoculture, all NK subpopulations expressed similar levels of
CD69, an early activation Ag (31) (p . 0.05, Fig. 2Ba). Upon
coculture with GBM cells at an E:T ratio of 1:1, only the sorted
KIR2DS2+ or gated KIR2DS2+ NK cells retained high levels of
CD69 (p , 0.0001, two-way ANOVA with Bonferroni multiple-
comparisons test), whereas KIR2DS22 donor NK cells and
KIR2DS22 sorted or gated subsets significantly downregulated
CD69 (Fig. 2Bb, representative dot plots Fig. 2Bc–f). Importantly,
the sorted or gated KIR2DS22 subsets diminished CD69 to
a greater extent (p , 0.001 and p , 0.05, respectively) than did
FIGURE 1. Ligation of NKG2D to
stress-induced ligands and the acti-
vating KIR2DS2 receptor are impor-
tant for efficient NK cell–mediated
cytotoxicity of GBM cells. (A) Sur-
face expression of ligands for NKG2D
receptors MICB, MICA, ULBP3, and
ULBP 2/5/6 on P3 (Aa–Ad), 2011-20-
I (Ae–Ah), and 2012-018 (Ai–Al)
cells. Dashed graphs represent nega-
tive controls; filled graphs represent
staining. The proportion of specifi-
cally stained cells indicated was cal-
culated by subtracting the percentage
of isotype-control–positive cells from
the percentage of marker-positive
cells. The percentage lysis by NK cells
of P3 (B) and 2012-018 (C) GBM cells
at E:T ratios of 5:1, 10:1, and 20:1,
with and without addition of blocking
NKG2D or IgG1 isotype-control Abs.
Mean percentage (6 SEM) of lysis of
P3 (D) and 2012-018 (E) GBM cells
mediated by KIR2DS2+ or KIR2DS4+
NK cells compared with NK cells
lacking both receptors (negative) at E:
T ratios of 5:1, 10:1, and 20:1. Data are
mean 6 SEM of three or four inde-
pendent experiments/donor (n = 6
donors). The x-axis shows experi-
mental condition and E:T ratio (in
parentheses). *p , 0.05, **p = 0.01,
***p , 0.001. (F) CD56 versus
KIR2DS2 dot plots represent the gating
strategy of KIR2DS2+ subpopulations
of donors 3 (Fa), 6 (Fb), 7 (Fc), and 8
(Fd). CD56 versus KIR2DS4 dot plots
represent the gating strategy for
KIR2DS4+ expression on NK cell sub-
populations of donors 9 (Fe) and 10 (Ff).
Data are mean percentage (6 SEM) of
cells expressing KIR2DS2 or KIR2DS4
receptors. Mean percentage (6 SEM) of
lysis of P3 GBM cells (G), 2012-018
GBM cells (H), and K562 cells (I) me-
diated by NK cells from donors 6 and 7
(red: possessing KIR2DS2 gene and no
other activating KIR genes) compared
with NK cells from donors 4 and 5
(blue: lacking KIR2DS2 gene, but pos-
sessing three or more genes of other
activating KIRs) at E:T ratios of 2:1, 5:1,
10:1, and 20:1. Data are mean 6 SEM
of three or four independent experi-
ments/donor. *p , 0.05.
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immunogenotype-negative donor NK cells, indicating that the
KIR2DS2+ fractions were the activated subsets (Fig. 2Bb). In
contrast to CD69, only the monocultured sorted KIR2DS2+ or
gated KIR2DS2+ NK cells expressed significantly high levels of
CD16 (p , 0.0001, two-way ANOVA with Bonferroni multiple-
comparisons test, Fig. 2Ca), which also was retained in coculture
with GBM cells (p , 0,0001, Fig. 2Cb, representative dot plots
Fig. 2Cc–f). Immunogenotype-negative donor NK cells and
KIR2DS22 subsets did not differ significantly in their low CD16
expression levels before and after coculture with GBM (p . 0.05,
Fig. 2C). Furthermore, greater proportions of heterogeneous
KIR2DS2+ NK cells significantly expressed LAMP-1 (CD107a)
(p = 0.0040, Mann–Whitney U test, Fig. 2D), indicating that they
were activated for degranulation (32). There was no difference in
the expression of NKG2D, NKp46, and inhibitory KIRs in the
KIR2DS2+ and KIR2DS22 NK cell subsets (data not shown).
There also was no statistically significant difference in prolifera-
tion based on BrdU incorporation, Ki-67 labeling index, and ex-
pansion rates between the KIR2DS2+ and KIR2DS22 NK cell
subsets (data not shown).
Activated KIR2DS2 immunogenotype NK cells preferentially
express soluble CD137 and granzyme A lytic granules
Cytokine analyses revealed no significant difference in IFN-g,
TNF-a, perforin, or granzyme B release between KIR2DS2+ and
KIR2DS22 NK cells in monoculture or coculture (Supplemental
Fig. 2). However, release of the splice variant of costimulatory
receptor soluble CD137 (sCD137; ILA) (33), a member of the
TNFR family, was significantly enhanced in the KIR2DS2+ sorted
NK cell subsets in monoculture compared with KIR2DS22 sorted
subsets (p , 0.001, one-way ANOVA, Fig. 2Ea), as well as in 1:1
cocultures with GBM cells (p , 0.05, one-way ANOVA with
Bonferroni multiple-comparisons test, Fig. 2Ea); however, it
was not significantly different from immunogenotype KIR2DS22
donors. Although levels of perforin and granzyme B cytolytic
granules could not differentiate the NK cells from immunogeno-
type KIR2DS22 donors and FACS-sorted subsets from KIR2DS2+
donors (Supplemental Fig. 2), granzyme A release was signifi-
cantly elevated in the KIR2DS2+ sorted subsets compared with
KIR2DS22 sorted subsets and in NK cells from immunogenotype
KIR2DS22 donors in monoculture, as well as in 1:1 coculture
with GBM cells (p , 0.05 and p , 0.01 respectively, one-way
ANOVA with Bonferroni multiple-comparisons test, Fig. 2Eb).
These data collectively indicate that the KIR2DS2+ subset is
distinct from the KIR2DS22 subset, as well as KIR2DS22 NK
cells from immunogenotype-negative donors, with regard to in-
trinsic activation states, degranulation, and cytotoxic capacity.
Treatment with a single dose of NK cells significantly increases
survival of GBM-bearing animals
Next, we asked whether NK cells’ efficacy against solid GBM
in vivo is dependent on the KIR repertoire. Thus, we treated mice
bearing human GBM with activated NK cells isolated from
donors 3 and 4, who possessed different inhibitory and activat-
ing KIR gene repertoires (Table II). Donor 3 NK cells possessed
a KIR2DS2+ genotype but had no inhibitory KIR-HLA ligand
Table II. The KIR genotypes of donors’ NK cells and the HLA genotype of P3 GBM cells, 2011-20-I GBM cells, and 2012-018 gliosarcoma
Legend colors: red, – NK or GBM cells are positive for KIR or HLA ligand, respectively; green, - NK or GBM cells are negative for KIR or HLA ligand, white, – HLA
ligand is unknown; yellow highlights, donors used in in vivo experiments. Mismatch is denoted by two different colors from group HLA and KIR, match is denoted by two
red colors.
**C2 epitope recognized by KIR2DL2/3.
+, NK cells positive for KIR or HLA gene; –, sample negative for KIR or HLA gene; +del, NK cells have partial deletion KIR2DS4.
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mismatch. In contrast, donor 4 NK cells had three inhibitory KIR-
HLA ligand mismatches but lacked the KIR2DS2 gene. MRI
performed 26 d after implantation of the GBM tumor spheres
(12 d after injection of the first dose of NK cells) revealed
contrast-enhancing small tumor lesions in the right hemisphere on
postcontrast T1-weighted images from control mice and mice that
received a single dose of NK cells from donor 3 or donor 4
(Fig. 3A, right panels). In all mice scanned, T2-weighted
sequences displayed high signal intensities in the same areas,
consistent with localized edema formation indicative of tumor
development (Fig. 3A, left panels). H&E staining performed post
mortem showed diffuse infiltrative tumors with high cellular
density in the control group (Fig. 3B) and large regions of necrotic
cell death in the treatment groups (Fig. 3B). The Ki-67–labeling
FIGURE 2. Activating KIR2DS2 receptor con-
tributes to a functional advantage for NK cells. (A)
Gating strategy of KIR2DS2 subpopulations from
NK cell donors. (Aa) CD56 versus KIR2DS2 dot plot
showing NK cell gating of KIR2DS22 donors. (Ab)
CD56 versus KIR2DS2 dot plot showing NK cell
gating of KIR2DS2+ donors. KIR2DS22 and
KIR2DS2+ subpopulations are gated. (Ac) KIR2DS2
graph of the KIR2DS2+ donors. KIR2DS22 and
KIR2DS2+ subpopulations are gated. (Ad) KIR2DS2
graph of the KIR2DS2+ gated subpopulation of
KIR2DS2+ donors. (Ae) KIR2DS2 graph of the
KIR2DS22 gated subpopulation of KIR2DS2+
donors. (Af) KIR2DS2 versus FSC dot plot repre-
sentative of the KIR2DS2+ and KIR2DS22 sorting
procedure of KIR2DS2+ donors. KIR2DS22 and
KIR2DS2+ subpopulations are gated. Data are mean
percentage (6 SEM) of cells. (Ag) KIR2DS2 graph
of KIR2DS2+ sorted cells, obtained after 2 wk in
culture following the initial sorting. KIR2DS22 and
KIR2DS2+ subpopulations are gated. (Ah) KIR2DS2
graph of KIR2DS2+ gated subpopulation of
KIR2DS2+ sorted cells. (Ai) KIR2DS2 graph of
KIR2DS22 gated subpopulation of KIR2DS2+ sorted
cells. (Aj) KIR2DS2 graph of KIR2DS22 sorted
cells, obtained after 2 wk in culture following the
initial sorting. Data are mean percentage (6 SEM)
of cells. Dashed histograms represent negative con-
trol (immunogenotype KIR2DS22 donor stained for
KIR2DS2) and filled black histograms represent
gated or sorted population stained for KIR2DS2. (B)
Percentage of cells from each of the subpopulation
described above expressing the CD69 surface recep-
tor when cultured as monoculture 1:0 (Ba) or cocul-
tured with P3 GBM (1:1) (Bb). Dot plots of CD56
versus CD69 for gated KIR2DS2+ (Bc and Bd)
and gated KIR2DS22 (Be and Bf) subpopulations
when cultured as monoculture 1:0 or cocultured with
P3 (1:1). (C) Percentage of cells of each subpopula-
tion described above expressing the CD16 surface
receptor when cultured as monoculture 1:0 (Ca) or
cocultured with P3 (1:1) (Cb). Dot plots of CD56
versus CD16 of the gated KIR2DS2+ (Cc and Cd) and
gated KIR2DS22 (e and f) subpopulations when
cultured as monoculture 1:0 or cocultured with P3
(1:1). (Da) Percentage of cells of the KIR2DS22 and
KIR2DS2+ donors expressing the CD107a surface
receptor. (Db) Representative CD107a graph of
KIR2DS22 donors (filled gray), KIR2DS2+ donors
(filled black), and negative controls (dashed line).
Data are mean percentage (6 SEM) of positive cells.
Dot plots of CD56 versus CD107a of the KIR2DS22
(Dc) and KIR2DS2+ (Dd) donors. (E) Concentration
(pg/ml) of sCD137 (Ea) and granzyme A (Eb) in the
supernatant of cultures of different subpopulations of
NK cells in monocultures 1:0 or in cocultures with P3
(1:1) for 4 h in serum-free RPMI 1640 without cy-
tokine supplement. Data are mean 6 SEM of three
or four independent experiments/donor. *p , 0.05,
**p , 0.01, ***p , 0.001, ****p , 0.0001.
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FIGURE 3. Treatment with a single dose of NK cells significantly increases animal survival. (A) T2-weighted and postcontrast T1-weighted images of
NOD/SCID mice bearing P3 tumors treated with one dose of NK cells from donor 4 or donor 3 or controls. Tumors are indicated by arrowheads. (B) H&E
staining of tumors treated with donor 3–derived or donor 4–derived NK cells. Necrosis is indicated by arrowheads (scale bar, 100 mm; original magni-
fication 3200). (C) Ki-67+ cells (scale bar, 100 mm; original magnification 3400). Percentage Ki-67–positive (D) and cell death as represented by the
percentage of TUNEL+ apoptotic/necrotic cells (E). Data are mean6 SEM. (F) Kaplan–Meier survival curves of animals treated with vehicle PBS/CD2 and
NKp46 Abs (n = 10 animals) or with one or two doses of NK cells from donor 4 or donor 3 (n = 7 animals/group). (G) CD31 immunostaining from control
mouse and mice that received one dose of NK cells from donor 4 or donor 3 (scale bar, 100 mm; original magnification 3200). Microvascular density (H)
and percentage of area positive for CD31 microvessels (I). *p , 0.05, ***p , 0.001.
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FIGURE 4. Increased proinflammatory macrophages/microglia within the tumor after one-dose NK cell treatment. (A) Longitudinal T2-weighted (upper
panels) and postcontrast T1-weighted (lower panels) images of NOD/SCID mice bearing P3 tumors before (12 d) and after treatment with one or two doses
(19 and 26 d, respectively) of NK cells from donor 4. (B) H&E staining of tumor-bearing mouse brain after two doses of donor 3 NK cells. Immune
infiltrates in the contralateral hemisphere region as indicated by the white box in (A) (scale bar, 100 mm; original magnification3200). Inset shows a whole-
brain histological section stained with H&E from the white box region on MR images from a representative animal treated with donor 4–derived NK cells.
(C) Longitudinal T2-weighted (upper panels) and postcontrast T1-weighted (lower panels) images of NOD/SCID mice bearing P3 tumors before (12 d) and
after treatment with one or two doses (19 and 26 d, respectively) of NK cells from donor 3. (D) H&E staining of tumor-bearing mouse brain after two doses
of donor 4 NK cells. Immune infiltrates in the contralateral hemisphere region as indicated by the white box in (C) (scale bar, 100 mm; original magni-
fication 3200). Inset shows a whole-brain histological section stained with H&E from the white box region on MR images from (Figure legend continues)
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index revealed greater tumor cell proliferation in untreated control
tumors compared with tumors treated with one dose of NK cells
from donor 3 or donor 4 (Fig. 3C, 3D). Donor 3’s NK cells sig-
nificantly reduced tumor proliferation compared with controls
(p = 0.02, one-way ANOVA, Kruskal–Wallis 7.53, df = 2, Fig. 3D).
Larger areas of apoptotic cells were seen in the tumors treated
with donor 3’s NK cells compared with vehicle-treated control
tumors (p = 0.0004, one-way ANOVA, Kruskal Wallis 15.55,
df = 2, Fig. 3E) and with tumors treated with donor 4’s NK cells
(p = 0.04, one-way ANOVA, Kruskal–Wallis 15.55, df = 2,
Fig. 3E). There was no significant difference in the survival of
animals in control groups treated with PBS vehicle only and
animals treated with anti-CD2 and anti-NKp46 Abs, which are
components of NK cell expansion in the Miltenyi Biotec kit and
were used as controls (data not shown). Therefore, we merged
these animals into one control group. Mice treated with a single
dose of 106 NK cells obtained from donor 4 or donor 3 lived
significantly longer than did untreated control animals, with a
median survival of 117.5 d (p = 0.0005, log-rank 15.62, df = 1),
163 d (p = 0.0001, log-rank 12.24, df = 1), and 94 d, respectively
(Fig. 3F). There was no significant difference in the survival of
animals treated with one dose of NK cells obtained from donor 4
and donor 3 (p = 0.11, log-rank 2.45, df = 1, Fig. 3F). Moreover,
repeated doses of NK cells from both donor 3 and donor 4
significantly diminished the survival benefit compared with
a single dose of NK cells from donor 4 (p = 0.002, log-rank 8.89,
df = 1, Fig. 3F) or from donor 3 (p = 0.0004, log-rank 12.34, df = 1,
Fig. 3F). Next, we investigated angiogenesis as an indicator of
tumor growth and metabolism. Treatment with a single dose of
NK cells from donor 3 significantly reduced tumor microvascular
densities compared with NK cells from donor 4 (p = 0.04, one-
way ANOVA, Kruskal Wallis 6.0, df = 2, Fig. 3G, 3H). The
microvessels of tumors treated with donor 4 NK cells were dys-
regulated and dilated, indicating florid angiogenesis (Fig. 3G), as
revealed by a significantly larger fraction of CD31+ vessels
compared with tumors treated with donor 3 NK cells (p = 0.01,
one-way ANOVA, Kruskal–Wallis 8.0, df = 3, Fig. 3I).
Increased proinflammatory macrophages/microglia within the
tumor after one dose of NK cells
We hypothesized that the repeated NK cell treatments reduced
animal survival as the result of increased inflammation. Longitu-
dinal T1- and T2-weighted MRI follow-up revealed radiological
changes that appeared after the second dose of NK cells from both
donors (Fig. 4A, 4C). Histological analysis revealed numerous
immune cells at the ipsilateral sites of tumor implantation and in
the contralateral hemisphere, destruction of the white matter tracts
of the corpus callosum, and high numbers of foamy cells (Fig. 4B,
4D). To characterize the cell types involved, flow cytometry was
performed on brain tissue dissociated into a single-cell suspen-
sion. We distinguished macrophages from microglia based on the
relative expression of CD45 and CD11b (34); the CD45high
CD11b+ cellular populations represented macrophages, and
CD45lowCD11b+ cells were microglia (Fig. 4E). Although pro-
portions of microglia remained unchanged between controls and
tumors treated with one or two doses of NK cells (p . 0.05,
Fig. 4F), macrophages were significantly recruited to the tumors
after treatment with one or two doses of NK cells (p = 0.005, one-
way ANOVA, Kruskal–Wallis 10.26, df = 2, Fig. 4I). The macro-
phages significantly increased costimulatory CD40 molecules
after one dose of NK cell treatment compared with two doses of
treatment (p = 0.02, one-way ANOVA, Kruskal–Wallis 7.46, df = 2,
Fig. 4J), whereas this was not the case for microglia (Fig. 4G).
Single-dose NK cell treatment significantly increased F4/80 ex-
pression on macrophages compared with the control and two
doses of NK cells (p = 0.0045, one-way ANOVA, Kruskal–Wallis
10.79, df = 2, Fig. 4K). Microglia showed a tendency toward ele-
vated IL-7R (CD127) expression compared with the control group
and the group that received two doses of NK cells (p = 0.061, one-
way ANOVA, Kruskal–Wallis 5.5, df = 2, Fig. 4H). Off-target
experiments with the two-dose NK cell regimen from immuno-
genotype KIR2DS2+ (donor 3) and KIR2DS22 NK cells (donor 4)
in a separate cohort of nontumor-bearing mice demonstrated that
NK cells were well tolerated, because the animals were alive at
4 mo post transplantation (p = 0.38, log-rank 4.16, df = 4, data not
shown). Histological analyses of brains revealed normal histo-
architecture and regenerating tissue in areas of NK cell injection
(Fig. 4L, 4M). Significantly more CD56+CD32 NK cells that were
CD16+ from KIR2DS2+ donor 3 persisted in the brain (p = 0,03;
two-way ANOVA with Bonferroni multiple-comparisons test) at
3 wk compared with the KIR2DS22 donor 4 NK cells (Fig. 4N–Q).
There was no difference in proliferation, as indicated by the Ki-67–
labeling index (data not shown), at 1, 3, and 5 wk posttransplant.
Single-dose NK cell treatment upregulates nestin and
HLA-ABC expression on tumor cells
We identified the human cells engrafted in the mouse brains using
human-specific STEM121, which labeled highly cellular control
tumors, donor 4 NK cell–treated tumors, and donor 3 NK cell–
treated tumors with extensive areas of tumor necrosis (Fig. 5A).
Tumor cells were confirmed by their expression of human-specific
nestin (Fig. 5A). NKp46+ NK cells could be visualized in the
tumor tissues (Fig. 5B, 5C) from all treatment groups. Flow cyto-
metric phenotyping of the mouse brains revealed that one dose of
NK cells upregulated the expression of nestin, which manifested as
a higher proportion of nestinbright tumor cells, compared with controls
and mice treated with a double dose of NK cells (41.06 9.6% versus
3.16 2.8%, p. 0.05, and versus 2.36 2.3%, p, 0.05, respectively,
n = 6, Fig. 5D, 5E). Tumor cells from mice treated with one dose of
NK cells upregulated the expression of HLA-A, HLA-B, and HLA-C
compared with the control group (58.06 11.78% versus 5.56 4.3%,
p , 0.05, n = 6, Fig. 5F, 5G) and compared with mice treated with
a double dose of NK cells (58.0 6 11.78% versus 6.6 6 4.1%, p .
0.05, n = 6, Fig. 5F, 5G), thus potentially providing ligands for KIRs.
a representative animal treated with donor 3–derived NK cells. (E) Representative examples of flow cytometry gating of microglia (CD45lowCD11b+) and
macrophage (CD45highCD11b+) populations of the control group (top panel) and the groups that received one dose (middle panel) or two doses (bottom
panel) of NK cells. (F) Proportions of microglia within all immune (CD45+) cells as evaluated by flow cytometry. Data are mean 6 SEM (n = 6/group).
Proportions of microglia expressing CD40 (G) or CD127 (H), as evaluated by flow cytometry. Data are mean 6 SEM (n = 6/group). (I) Proportions of
macrophages within all immune (CD45+) cells, as evaluated by flow cytometry. Data are mean 6 SEM (n = 6/group). Proportions of macrophages
expressing CD40 (J) or F4/80 (K), as evaluated by flow cytometry. Data are mean 6 SEM (n = 6/group). Histological H&E staining of nontumor-
bearing mouse brain after two doses of donor 4 NK cells (L) or two doses of donor 3 NK cells (M) (scale bar, 10 mm; original magnification 3400).
Percentage of donor 3 and donor 4 NK cells (CD56+ and CD32) (N) and CD16+ NK cells (O) in nontumor–bearing mouse brains 1, 3, and 5 wk after
NK cell treatment. Dot plots of CD16 versus FSC showing the percentage of CD16+ cells present 3 wk after donor 3 (P) or donor 4 (Q) NK cell
treatment. *p , 0.05.
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Tumor cells from all treatment groups expressed low levels of HLA-E
(,4%) and HLA-G (,9%, data not shown), thereby lacking ligands
for the inhibitory/activating receptors NKG2A and KIR2DL4, re-
spectively, expressed on NK cells.
FIGURE 5. Single-dose NK cell treatment induces nestin, HLA-A, HLA-B, and HLA-C expression on tumor cells. (A) Human-specific STEM121+ cells
in P3 tumor-bearing mice treated with vehicle controls or one dose of NK cells from donor 4 or donor 3 (scale bar, 100 mm; original magnification 3200).
Nestin expression by IHC in tumors treated with one dose of NK cells from donor 4 or donor 3 compared with controls post mortem (scale bar, 100 mm;
original magnification 3200). White arrowheads in (A) indicate regions of necrotic tumor tissue. (B) Human-specific NKp46 staining demonstrates in-
filtration of the injected NK cells into the tumor in vivo (right panel) and staining of human tonsil used as a positive control (left panel) (scale bar, 10 mm;
original magnification 3400). (C) Percentage of NKp46+ cells (mean 6 SEM) in tumor tissue. (D) Representative graphs showing nestin expression on
tumor cells from control animals and animals treated with one or two doses of NK cells, as evaluated by flow cytometry. The gate represents the “nestinbright”
population within all tumor (nestin+) cells (red: negative control; pink: nestin). (E) Proportion of nestinbright population within all tumor (nestin+) cells, as
evaluated by flow cytometry. Data are mean 6 SEM (n = 6/group). (F) Representative graphs showing HLA-A,B,C expression on tumor cells from control
animals and animals treated with one or two doses of NK cells, as evaluated by flow cytometry. The gate represents the HLA-A,B,C+ population within all
tumor (nestin+) cells (blue: isotype control; pale blue: HLA-A,B,C). (G) Proportions of HLA-A,B,C+ population within all tumor (nestin+) cells, as evaluated by
flow cytometry. Data are mean 6 SEM (n = 6/group). *p , 0.05, **p , 0.01.
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NK cells play an important role in anticancer immunity because of
their multiple mechanisms of recognizing and killing transformed
cells. The NCRs NKp30, NKp44, and NKp46 were demonstrated to
induce NK cell activation via recognition of tumor-associated Ags
(9, 35, 36). Overexpression of stress-induced ligands for NKG2D-
activating receptor on tumor cells also was shown to trigger NK
cell–mediated tumor cell lysis (37). The above-mentioned mech-
anisms determine NK cell potency in a tumor-dependent manner,
because NCRs and NKG2D are constitutively expressed on NK
cells in most individuals, whereas different tumors variably ex-
press tumor-associated Ags and may display different expression
levels of NKG2D ligands.
In the current study, we investigated the cytotoxicity of human
allogeneic NK cells against patient-derived GBM and gliosarcoma
cells. These tumor cells were propagated in stem cell medium to
maintain the genomic and phenotypic heterogeneity, as well as the
cancer-initiating properties of the original tumor in situ (27, 38).
These aggressive, therapy-resistant GSCs were demonstrated to be
more susceptible to NK cell–mediated lysis (26). Our patient-
derived GBMs and gliosarcoma cells displayed phenotypes con-
sistent with immature GSCs, because they expressed the stem cell
markers CD133 and A2B5, propagated as neurospheres, and de-
rived tumors in vivo in mice, features that are consistent with
other reports (26, 27). Furthermore, nearly 100% of the GBM
cells expressed HLA-A, HLA-B, and HLA-C molecules, whereas
25.2% of gliosarcoma cells also expressed nonclassical HLA-E,
confirming our previous analyses of patients’ GBM biopsies in
situ (6). Purified and ex vivo–cultured NK cells obtained from 10
unrelated donors were cytotoxic against all GBMs, as well as
control K562 cells that lack HLA ligands. However, the glio-
sarcoma cells were less susceptible to NK cell–mediated lysis,
likely as a result of higher HLA levels and lower expression of
most of the ligands for NKG2D-activating receptor. This is sup-
ported by our findings demonstrating that blocking the NKG2D
receptor significantly diminished cytotoxicity against both P3 and
2012-018 cells. However, the NK cells’ cytotoxicity against GBM
cells was donor dependent, so we hypothesized that this was due
to their different KIR repertoires. The KIR-HLA class I mismatch
was reported to mediate the graft-versus-leukemia effect (18),
improve the outcome of patients receiving HSCT (18), and play an
important role in the NK cells’ cytotoxicity against solid tumors
in vitro (21, 29). However, we found no correlation between NK
cell potency and the degree of inhibitory KIR-HLA class I ligand
mismatch. A caveat to these interpretations is our small donor/
tumor sample size, which may not represent the diversity of the
NK repertoire (39), as well as the fact that we did not examine
allelic polymorphisms that were demonstrated to influence the
impact of KIR-HLA ligand mismatch on hematological malig-
nancies (40). Nevertheless, we investigated the possible impact of
activating KIRs on the efficacy of NK cell–mediated lysis of GBM
cells. Although activating KIRs often recognize the same ligands
as the inhibitory KIRs, they do so with lower affinity. KIR2DS2
does not bind well to HLA-C, and only substitution of a tyrosine
residue at position 45 of KIR2DS2 restores some binding affinity
to HLA-C (30). Therefore, the physiological function of activating
KIRs has remained elusive (41); until recently, activating KIRs
were not considered to play a major role in cancer. Our data in-
dicate that the KIR2DS2 gene may identify alloreactive NK cell
subsets with higher potency against GBM, independently of the
repertoire of inhibitory or other activating KIRs. KIR2DS4+ NK cells
were more potent against GBM than were KIR2DS22/KIR2DS42
NK cells, but they were not significantly more potent than
KIR2DS2+ NK cells. Recently, HLA-A*11:01 was demonstrated
to bind KIR2DS2 (30); however, the KIR2DS2+ NK cells ex-
hibited greater cytotoxic potency against all GBMs without HLA-
A*11:01 ligands, as well as K562 cells lacking all HLA ligands.
These findings might indicate that an intrinsic cytotoxic potency,
rather than KIR–HLA ligand interactions, is the mechanism of
potency associated with the KIR2DS2 immunogenotype. How-
ever, the existence of other, unidentified ligands cannot be ruled
out. We were unable to unequivocally demonstrate the impact
of KIR2DS2 and KIR2DS4 because KIR2DS2 and KIR2DS4
receptors were expressed at the protein level on only a minor
subpopulation of NK cells in contrast to NKG2D, which is con-
stitutively expressed on all NK cells; the anti-KIR2DS2 and anti-
KIR2DS4 Abs that we used are not known to have a blocking,
neutralizing, or stimulating effect; and high linkage disequilibrium
between KIR2DS2 and KIR2DL2 genes—only 4 aa residues
distinguish them at the ligand-binding domain–means that Abs
against KIR2DS2 might also recognize KIR2DL2. Generating
highly specific neutralizing monoclonal anti-KIR2DS2 and anti-
KIR2DS4 Abs, as well as an NK cell culture protocol that allows
the selective expansion of KIR2DS2+ or KIR2DS4+ cells, might
enable functional investigations of the role of KIR2DS2 and
KIR2DS4 receptors in NK cell–mediated lysis of tumor cells.
Despite these shortcomings, we demonstrated functionally that
KIR2DS2+-enriched NK cell subsets retained significantly higher
levels of CD69 and CD16 and secreted significantly more sCD137,
which might regulate their activation. The increased cytotoxic
potential of KIR2DS2+ NK cells was consistent with significantly
higher intrinsic levels of CD107a+ cytolytic lysosomes and in-
creased granzyme A degranulation, when in contact with GBM
cells, compared with KIR2DS22 NK cell subsets and NK cells
from immunogenotype KIR2DS22. Human granzyme A is a serine
protease with trypsin-like activity; it cleaves basic arginine and
lysine residues to induce rapid caspase-independent cell death
through ssDNA breaks (42, 43). Thus, tumor cells that are resistant
to caspase-mediated cell death, including GBMs that overexpress
Bcl-2, might be sensitive to the apoptotic effects of granzyme
A. More KIR2DS2+ NK cells also persisted in vivo at 3 wk,
consistent with increased sCD137 costimulatory factors.
Furthermore, we investigated the impact of KIR repertoires on
the NK cells’ potency against solid GBM in vivo and demonstrated
that donor 3’s NK cells, which possessed the KIR2DS2+ gene,
prolonged median survival by 72 d compared with control and by
46 d compared with donor 4’s KIR2DS22 NK cells, and man-
ifested as decreased tumor proliferation, reduced angiogenesis,
and increased apoptosis. We reported recently that early structural,
contrast-enhanced MRI imaging fails to distinguish tumor vol-
umes in immunotherapy strategies (44); thus, we used it in this
study to visualize tumor establishment. Based on these in vivo
findings and the in vitro findings, we speculate that the differ-
ence in the outcome of the animals partially corresponds to the
alloreactive KIR2DS2+ NK cells. Despite less inhibitory KIR-
HLA class I mismatch, donor 3’s NK cells demonstrated better
therapeutic efficacy, indicating that the inhibitory signal resulting
from interactions of inhibitory KIR with their ligands may be
overridden by activating signals mediated by KIR2DS2, in addi-
tion to other activating receptors, such as NCRs and NKG2D.
Moreover, NK cells from donor 4 were less efficient, despite the
presence of three other activating KIR genes; this may suggest that
the KIR2DS2 genotype represents a dominant activation signal.
However, this finding requires confirmation in larger cohorts of
donor/tumor samples for which the KIR diversity is more exten-
sively accounted. Nevertheless, our study suggests that KIR2DS2
may constitute an important clinical criterion for NK cell donor
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selection with regard to the development of effective cell-based
anticancer therapies.
The lack of extended survival in double dose–treated, tumor-
bearing animals may reflect an “on-target” adverse effect that
occurs as the result of extensive inflammation due to host mac-
rophage recruitment, in addition to tumor-dependent factors. Off-
target experiments that treated naive nontumor-bearing mice with
the same NK cell schedule showed that it was well tolerated; it
did not result in dose-dependent toxicity. Compared with double
dose–treated and control animals, a higher proportion of macro-
phages from single dose–treated tumor-bearing animals expressed
CD40, a costimulatory receptor that interacts with the CD154 li-
gand that is reported to be expressed on NK cells (45). The
microglia of single dose–treated animals upregulated the expres-
sion of CD127, the IL-7R that mediates inflammation (46, 47);
thus, the increased expression of its receptor may suggest an in-
duced proinflammatory response of host microglia that, in addi-
tion to host CD40-expressing macrophages, might contribute to
the beneficial effect of single-dose treatment. In our previous
study using a rat glioma model, we proposed a mechanism of
NK cell–mediated immune modulation of microglia to proin-
flammatory phenotypes through IFN-g secretion and recruitment
of M1-like macrophages from the periphery (48). In that study,
combination treatment with NK cells and mAb9.2.27 against
NG2/CSPG4 induced the functional switch of microglia from
tumor supportive, anti-inflammatory M2-like cells to proin-
flammatory M1-like cells that effectively reduced GBM growth
in vivo. We speculate that a similar cross-talk between macro-
phages and microglia, in response to NK cell–derived factors,
occurred in the current study. In addition, nestin expression was
upregulated on the tumor cells of animals treated with a single
dose of NK cells compared with double dose–treated animals and
controls. The nestin intermediate filament is expressed on neural
progenitor cells under physiological conditions and is attenuated
upon differentiation of neural stem cells. However, nestin is
overexpressed in glioma cells, reactive astrocytes (49), and it can
be re-expressed during other pathological conditions, such as in-
jury- or infection-related inflammation (50, 51). Thus, we specu-
late that the increased nestin expression on tumor cells in single
dose–treated animals is associated with the proinflammatory
effects mediated by the adoptively transferred NK cells. Tumor
cells in single dose–treated animals upregulated the expression of
HLA class I molecules compared with controls. Reddy et al. (52)
demonstrated that glioma cell lines upregulated HLA class I ex-
pression in response to IFN-b and IFN-g treatment in vitro.
Therefore, the effect that we observed in vivo might be due to
IFN-g release by activated NK cells.
To investigate the influence of KIR–HLA class I interactions on
the therapeutic effect, we chose to use NOD/SCID mice bearing
human tumor and human NK cells isolated from healthy donors.
Xenograft models using patient-derived tumor material are con-
sidered to be more representative, and lack of functional host NK
cells in NOD/SCID mice eliminates the possible influence of host
NK cells on the study results. However, the disadvantage of this
model is the inability to assess the full impact of the host immune
system, which is of great importance in the context of allogeneic
cellular therapy. Therefore, further studies are needed to eval-
uate whether allogeneic NK cell therapy is applicable for GBM
patients with respect to immune-conditioning regimens, mode of
delivery, dose escalation, maximum tolerated doses to the brain,
and management of acute local inflammation after NK cell infu-
sions. To summarize, the possibility of using NK cells against
solid tumors is a promising strategy that has just started to be
realized (53, 54). To our knowledge, our study is the first to
demonstrate that KIR2DS2+ NK cells may represent an allo-
reactive subset with potent cytotoxicity against patient-derived
solid GBM tumors in vivo mediated by elevated activation
levels and effective granzymes against GBM. The impact of
KIR2DS2 should be investigated further in a larger cohort, because
it may identify donors with more potent NK cells. Selective ex-
pansion of NK cells with the desired phenotype could enhance
anticancer therapeutics.
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41. López-Botet, M., T. Bellón, M. Llano, F. Navarro, P. Garcı́a, and M. de Miguel.
2000. Paired inhibitory and triggering NK cell receptors for HLA class I mol-
ecules. Hum. Immunol. 61: 7–17.
42. Beresford, P. J., Z. Xia, A. H. Greenberg, and J. Lieberman. 1999. Granzyme A
loading induces rapid cytolysis and a novel form of DNA damage independently
of caspase activation. Immunity 10: 585–594.
43. Lieberman, J., and Z. Fan. 2003. Nuclear war: the granzyme A-bomb. Curr.
Opin. Immunol. 15: 553–559.
44. Rygh, C. B., J. Wang, M. Thuen, A. Gras Navarro, E. M. Huuse, F. Thorsen,
A. Poli, J. Zimmer, O. Haraldseth, S. A. Lie, et al. 2014. Dynamic Contrast
Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunother-
apy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma. PloS One
9: e108414.
45. Scott, M. J., J. J. Hoth, M. K. Stagner, S. A. Gardner, J. C. Peyton, and
W. G. Cheadle. 2004. CD40-CD154 interactions between macrophages and
natural killer cells during sepsis are critical for macrophage activation and are
not interferon gamma dependent. Clin. Exp. Immunol. 137: 469–477.
46. Fry, T. J., and C. L. Mackall. 2002. Interleukin-7: from bench to clinic. Blood 99:
3892–3904.
47. Hartgring, S. A., J. A. van Roon, M. Wenting-van Wijk, K. M. Jacobs,
Z. N. Jahangier, C. R. Willis, J. W. Bijlsma, and F. P. Lafeber. 2009. Elevated
expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-
induced immune activation in rheumatoid arthritis. Arthritis Rheum. 60: 2595–
2605.
48. Poli, A., J. Wang, O. Domingues, J. Planagumà, T. Yan, C. B. Rygh,
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